Anti—IL2R Immunotoxins

References

• Wong-Staal F., Gallo R.C. Human T-lympho-tropic retroviruses. Nature 1985; 317: 395–403
   PubMed Web of Science ®Google Scholar
• Foon K.A., Rai K.R., Gale R.P. Chronic lymphocytic leukemia: new insights into biology and therapy. Ann. Intern. Med. 1990; 113: 525–539
   PubMed Web of Science ®Google Scholar
• Blattner W.A., Takatsuki K., Gallo R.C. Hu man T-cell leukemia-lymphoma virus and adult T-cell leukemia. J. Am. Med. Assoc. 1983; 250: 1074–1080
   PubMed Web of Science ®Google Scholar
• Shimoyama M. Diagnostic criteria and classification of clinical subtypes of adult T-cell leukemia-lymphoma. A report from the Lymphoma Study Group (1984–1987). Br. J. Haematol. 1991; 79: 428–437
   PubMed Web of Science ®Google Scholar
• Rozman C., Montserrat E., Feliu E., Granena A., Marin P., Nomdedeu B., Vives Corrons J.L. Prognosis of chronic lymphocytic leukemia: a multivariate survival analysis of 150 cases. Blood 1982; 59: 1001–1005
   PubMed Web of Science ®Google Scholar
• Yagura H., Tamaki T., Furitsu T., Tomiyama Y., Nish-Iura T., Tominaga N., Katagiri S., Yonezawa T., Tarui S. Demonstration of high-affinity interleukin-2 receptors on B-chronic lymphocytic leukemia cells: functional and structural characterization. Blut 1990; 60: 181–186
   PubMedGoogle Scholar
• Kodaka T., Uchiyama T., Ishikawa T., Kamio M., Oni-Shi R., Itoh K., Hori T., Uchino H., Tsudo M., Araki K. Interleukin-2 receptor β-chain (p70–75) ex pressed on leukemic cells from adult T cell leukemia patients. Jpn. J. Cancer Res. 1990; 81: 902–908
   PubMedGoogle Scholar
• Waldmann T.A. The interleukin-2 receptor. J. Biol. Chem. 1991; 266: 2681–2684
   PubMed Web of Science ®Google Scholar
• Waldmann T.A. The structure, function, and expression of interleukin-2 receptors on normal and malignant lymphocytes. Science 1986; 232: 727–732
   PubMed Web of Science ®Google Scholar
• Bacha P., Williams D.P., Waters C., Williams J.M., Murphy 3.R., Strom T.B. Interleukin 2 receptor-targeted cytotoxicity: Interleukin 2 receptor-mediated action of a diphtheria toxin-related interleukin 2 fusion protein. J. Exp. Med. 1988; 167: 612–622
   PubMed Web of Science ®Google Scholar
• Kirkman R.L., Bacha P., Barrett L.V., Forte S., Murphy J.R., Strom T.B. Prolongation of cardiac allograft survival in murine recipients treated with a diphtheria toxin-related interleukin-2 fusion protein. Transplantation 1989; 47: 327–330
   PubMed Web of Science ®Google Scholar
• LeMaistre C.F., Meneghetti C., Rosenblum M., Reuben J., Parker K., Shaw J., Deisseroth A., Woodworth T., Parkinson D.R. Phase I trial of an interleukin-2 (IL-2) fusion toxin (DAB486IL-2) in hematologic malignancies ex pressing the IL-2 receptor. Blood 1992; 79: 2547–2554
   PubMed Web of Science ®Google Scholar
• Kuzel T., Rosen S., Gordon L., Winter J., Samuelson E., Kaul K., Roenigk H., Nylen P., Woodworth T. Safety and biologic effects of DAB486IL-2 in IL-2 receptor expressing malignancies. Proc. Am. Assoc. Cancer Res. 1992; 33: 1358
   Google Scholar
• Foss F., Borkowski T., Tompkins A., Gilliom M., Cooper M., Udey M., Stetler-Stevenson M., Jaffe E., Woodworth T., Sausville E. Pilot phase II study of a DAB486dL-2 fusion toxin in cutaneous T-cell lymphoma. Proc. Am. As Soc. Cancer Res. 1993; 34: 1236
   Google Scholar
• Williams D.P., Snider C.E., Strom T.B., Murphy J.R. Structure/function analysis of interleukin-2-toxin (DAB486-IL-2): fragment B sequences required for the delivery of fragment A to the cytosol of target cells. J. Biol. Chem. 1990; 265: 11885–11889
   PubMed Web of Science ®Google Scholar
• Bacha P., Parker K., Nylen P., Nichols J.C., Wood worth T.W., The DAB389IL-2 Lymphoma Study Group. DAB389IL-2 fusion toxin evaluation in lymphoma clinical trials. Proc. Am. Assoc. Cancer Res. 1993; 34: 1237
   Google Scholar
• Waters C.A., Schimke P.A., Snider C.E., Itoh K., Smith K.A., Nichols J.C., Strom T.B., Murphy J.R. Interleukin 2 receptor-targeted cytotoxicity. Receptor binding requirements for entry of a diphtheria toxin-related interleukin 2 fusion protein into cells. Eur. J. Immunol. 1990; 20: 785–791
   PubMed Web of Science ®Google Scholar
• Takeshita T., Asao H., Ohtani K., Ishii N., Kumaki S., Tanaka N., Munakata H., Nakamura M., Sugamura K. Cloning of the γ chain of the human IL-2 receptor. Science 1992; 257: 379–382
   PubMed Web of Science ®Google Scholar
• Taniguchi T., Minami Y. The IL-2/IL-2 receptor system: A current overview. Cell 1993; 73: 5–8
   PubMed Web of Science ®Google Scholar
• Allured V.S., Collier R.J., Carroll S.F., McKay D.B. Structure of exotoxin A of Pseudomonas aeruginosa at 3.0-Ångstrom resolution. Proc. Natl. Acad. Sci. USA 1986; 83: 1320–1324
   PubMed Web of Science ®Google Scholar
• Hwang J., FitzGerald D.J., Adhya S., Pastan I. Functional domains of Pseudomonas exotoxin identified by deletion analysis of the gene expressed in E. coli. Cell 1987; 48: 129–136
   PubMed Web of Science ®Google Scholar
• Ogata M., Chaudhary V.K., Pastan I., FitzGerald D.J. Processing of Pseudomonas exotoxin by a cellular protease results in the generation of a 37,000-Da toxin fragment that is translocated to the cytosol. J. Biol. Chem. 1990; 265: 20678–20685
   PubMed Web of Science ®Google Scholar
• Ogata M., Fryling C.M., Pastan I., FitzGerald D.J. Cell-mediated cleavage of Pseudomonas exotoxin between Arg279 and Gly280 generates the enzymatically active fragment which translocates to the cytosol. J. Biol. Chem. 1992; 267: 25396–25401
   PubMed Web of Science ®Google Scholar
• Siegall C.B., Chaudhary V.K., FitzGerald D.J., Pas tan I. Functional analysis of domains II, Ib and III of Pseudomonas exotoxin. J. Biol. Chem. 1989; 264: 14256–14261
   PubMed Web of Science ®Google Scholar
• Seetharam S., Chaudhary V.K., FitzGerald D., Pastan I. Increased cytotoxic activity of Pseudomonas exotoxin and two chimeric toxins ending in KDEL. J. Biol. Chem. 1991; 266: 17376–17381
   PubMed Web of Science ®Google Scholar
• Lorberboum-Galski H., FitzGerald D., Chaudhary V., Adhya S., Pastan I. Cytotoxic activity of an inter leukin 2-Pseudomonas exotoxin chimeric protein produced in Escherichiacoli. Proc. Matl. Acad. Sci. USA 1988; 85: 1922–1926
   PubMed Web of Science ®Google Scholar
• Lorberboum-Galski H., Kozak R.W., Waldmann T.A., Bailon P., FitzGerald D. J. P., Pastan I. Inter leukin 2 (IL2) PE40 is cytotoxic to cells displaying either the p55 or p70 subunit of the IL2 receptor. J. Biol. Chem. 1988; 263: 18650–18656
   PubMed Web of Science ®Google Scholar
• Case J.P., Lorberboum-Galski H., Lafyatis R., Fitz-Gerald D., Wilder R.L., Pastan I. Chimeric cytotoxin IL2-PE40 delays and mitigates adjuvant-induced arthritis in rats. Proc. Natl. Acad. Sci. USA 1989; 86: 287–291
   PubMed Web of Science ®Google Scholar
• Lorberboum-Galski H., Barrett L.V., Kirkman R.L., Ogata M., Willingham M.C., FitzGerald D.J., Pastan I. Cardiac allograft survival in mice treated with IL-2-PE40. Proc. Natl. Acad. Sci. USA 1989; 86: 1008–1012
   PubMed Web of Science ®Google Scholar
• Kozak R.W., Lorberboum-Galski H., Jones L., Puri R.K., Willingham M.C., Malek T., FitzGerald D.J., Wald-Mann T.A., Pastan I. IL-2-PE40 prevents the development of tumors in mice injected with IL-2 receptor expressing EL4 transfectant tumor cells. J. Immunol. 1990; 145: 2766–2771
   PubMed Web of Science ®Google Scholar
• Depper J.M., Leonard W.J., Kronke M., Waldmann T.A., Greene W.C. Augmented T cell growth factor receptor expression in HTLV-1-infected human leukemic T cells. J. Immunol. 1984; 133: 1691–1695
   PubMed Web of Science ®Google Scholar
• Huston J.S., Levinson D., Mudgett-Hunter M., Tai M., Novotny J., Margolies M.N., Ridge R.J., Bruccoleri R.E., Haber E., Crea R., Oppermann H. Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in Escherichiacoli. Proc. Natl. Acad. Sci. USA 1988; 85: 5879–5883
   PubMed Web of Science ®Google Scholar
• Bird R.E., Hardman K.D., Jacobson J.W., Johnson S., Kaufman B.M., Lee S., Lee T., Pope S.H., Riordan G.S., Whitlow M. Single-chain antigen-binding proteins. Science 1988; 242: 423–426
   PubMed Web of Science ®Google Scholar
• Chaudhary V.K., Queen C., Junghans R.P., Waldmann T.A., FitzGerald D.J., Pastan I. A recombinant immunotoxin consisting of two antibody variable domains fused to Pseudomonas exotoxin. Nature 1989; 339: 394–397
   PubMed Web of Science ®Google Scholar
• Batra J.K., FitzGerald D., Gately M., Chaudhary V.K., Pastan I. Anti-Tac (Fv)-PE40: a single chain antibody Pseudomonas fusion protein directed at interleukin 2 receptor bearing cells. J. Biol. Chem. 1990; 265: 15198–15202
   PubMed Web of Science ®Google Scholar
• Kreitman R.J., Chaudhary V.K., Waldmann T., Wil lingham M.C., FitzGerald D.J., Pastan I. The recombinant immunotoxin anti-Tac (Fv)-Pseudomonas exotoxin 40 is cytotoxic toward peripheral blood malignant cells from patients with adult T-cell leukemia. Proc. Natl. Acad. Sci. USA 1990; 87: 8291–8295
   PubMed Web of Science ®Google Scholar
• Kreitman R.J., Batra J.K., Seetharam S., Chaudhary V.K., FitzGerald D.J., Pastan I. Single-chain immunotoxin fusions between anti-Tac and Pseudomonas exo toxin: relative importance of the two toxin disulfide bonds. Bioconj. Chem. 1993; 4: 112–120
   PubMed Web of Science ®Google Scholar
• Chaudhary V.K., Gallo M.G., FitzGerald D.J., Pas tan I. A recombinant single-chain immunotoxin composed of anti-Tac variable regions and a truncated diphtheria toxin. Proc. Natl. Acad. Sci. USA 1990; 87: 9491–9494
   PubMed Web of Science ®Google Scholar
• Chaudhary V.K., FitzGerald D.J., Pastan I. A proper amino terminus of diphtheria toxin is important for cytotoxicity. Biochem. Biophys. Res. Comm. 1991; 180: 545–551
   PubMed Web of Science ®Google Scholar
• Hatakeyama M., Minamoto S., Uchiyama T., Hardy R.R., Yamada G., Taniguchi T. Reconstitution of functional receptor for human interleukin-2 in mouse cells. Nature 1985; 318: 467–470
   PubMed Web of Science ®Google Scholar
• Robb R.J., Greene W.C. Internalization of in terleukin 2 is mediated by the β chain of the high-affinity interleukin 2 receptor. J. Exp. Med. 1987; 165: 1201–1206
   PubMed Web of Science ®Google Scholar
• Kreitman R.J., Chaudhary V.K., Waldmann T.A., Han-Chard B., Cranston B., FitzGerald D. J. P., Pastan I. Cytotoxic activities of recombinant immunotoxins composed of Pseudomonas toxin or diphtheria toxin toward lymphocytes from patients with adult T-cell leukemia. Leukemia 1993; 7: 553–562
   PubMed Web of Science ®Google Scholar
• Kreitman R.J., Chaudhary V.K., Kozak R.W., Fitz Gerald D. J. P., Waldmann T.A., Pastan I. Recombinant toxins containing the variable domains of the anti-Tac monoclonal antibody to the interleukin-2 receptor kill malignant cells from patients with chronic lymphocytic leukemia. Blood 1992; 80: 2344–2352
   PubMed Web of Science ®Google Scholar
• Lewis M.J., Pelham H. R. B. Sequence of a second human KDEL receptor. J. Mol. Biol. 1992; 226: 913–916
   PubMed Web of Science ®Google Scholar
• Lowenthal J.W., MacDonald H.R., Iacopetta B.J. Intracellular pathway of interleukin 2 following receptor-mediated endocytosis. Eur. J. Immunol. 1986; 16: 1461–1463
   PubMed Web of Science ®Google Scholar
• LeMaistre C.F., Rosenblum M.G., Reuben J.M., Par-Kison D.R., Meneghetti C.M., Parker K., Shaw J.P., Deisseroth A.B., Woodworth T. Therapeutic effects of genetically engineered toxin (DAB486IL-2) in patient with chronic lymphocytic leukaemia. Lancet 1991; 337: 1124–1125
   PubMed Web of Science ®Google Scholar
• Marcon L., Rubin L.A., Kurman C.C., Fritz M.E., Longo D.L., Uchiyama T., Edwards B.K., Nelson D.L. Elevated serum levels of soluble Tac peptide in adult T-cell leukemia: correlation with clinical status during chemotherapy. Ann. Intern. Med. 1988; 109: 274–279
   PubMed Web of Science ®Google Scholar
• Winkelstein A., Jordan P.S. Immune deficiencies in chronic lymphocytic leukemia and multiple myeloma. Clin. Rev. Allergy 1992; 10: 39–58
   PubMedGoogle Scholar
• Pai L.H., FitzGerald D.J., Tepper M., Scbacter B., Spitalny G., Pastan I. Inhibition of antibody response to Pseudomonas exotoxin and animmunotoxin containing Pseudomonas exotoxin by 15-deoxyspergualin in mice. Cancer Res. 1990; 50: 7750–7753
   PubMed Web of Science ®Google Scholar
• Sung C., Youle R.J., Dedrick R.L. Pharma-cokinetic analysis of immunotoxin uptake in solid tumors: role of plasma kinetics, capillary permeability and binding. Cancer Res. 1990; 50: 7382–7392
   PubMed Web of Science ®Google Scholar
• Visani G., Delwel R., Touw I., Bot F., Lowenberg B. Membrane receptors for interleukin 2 on hemato-poietic precursors in chronic myeloid leukemia. Blood 1987; 69: 1182–1187
   PubMed Web of Science ®Google Scholar
• Armitage R.J., Lai A.P., Roberts P.J., Cawley J.C. Certain myeloid cells possess receptors for inter leukin-2. Br. J. Haematol. 1986; 64: 799–807
   PubMed Web of Science ®Google Scholar
• Bemengo M.G., Fierro M.T., Novelli M., Lisa F., Appino A. Soluble interleukin-2 receptor in Sezary syndrome: its origin and clinical application. Br. J. Dermatol. 1993; 128: 124–129
   PubMed Web of Science ®Google Scholar
• Waldmann T.A., Greene W.C., Sarin P.S., Saxinger C., Blayney D.W., Blattner W.A., Goldman C.K., Bongiovanni K., Sharrow S., Depper J.M., Leonard W., Uchiyama T., Gallo R.C. Functional and phenotypic comparison of human T cell leukemia/lymphoma virus positive adult T cell leukemia with human T cell leuke mia/lymphorna virus negative sezary leukemia and their distinction using anti-Tac. J. Clin. Invest. 1984; 73: 1711–1718
   PubMed Web of Science ®Google Scholar
• Strauchen J.A., Breakstone B.A. IL-2 receptor expression in human lymphoid lesions: Immunohistochemical study of 166 cases. Am. J. Pathol. 1987; 126: 506–512
   PubMed Web of Science ®Google Scholar
• Casey T.T., Olson S.J., Cousar J.B., Collins R.D. Immunophenotypes of Reed-Stemberg cells: a study of 19 cases of Hodgkin's disease in plastic-embedded sections. Blood 1989; 74: 2624–2628
   PubMed Web of Science ®Google Scholar
• Trentin L., Zambello R., Benati C., Cassatella M., Agos-Tini C., Bulian P., Adami F., Carra G., Pizzolo G., Semenzato G. Expression and functional role of the p75 interleukin 2 receptor chain on leukemic hairy cells. Cancer Res. 1992; 52: 5223–5228
   PubMed Web of Science ®Google Scholar
• Reed M.H., Shapiro M.E., Milford E.L., Carpenter C.B., Kirkman R.L. Interleukin 2 receptor expression on peripheral blood lymphocytes in association with renal allograft rejection. Transplantation 1989; 48: 361–366
   PubMed Web of Science ®Google Scholar
• Tiberghien P., Racadot E., Lioure B., Delain M., Girard A., Wijdenes J., Plouvier E., Flesch M., Cahn J., Herve P. Soluble CD8, IL-2 receptor, and tumor necrosis factor-alpha levels in steroid-resistant acute graft-versus-host disease. Relation with subsequent response to anti-IL-2 receptor monoclonal antibody treatment. Transplantation 1991; 52: 475–481
   PubMed Web of Science ®Google Scholar
• Lemm G., Wamatz H. Evidence for enhanced interleukin 2 (IL-2) secretion and IL-2 receptor presentation by synovial fluid lymphocytes in rheumatoid arthritis. Clin. Exp. Immunol. 1986; 64: 71–79
   PubMed Web of Science ®Google Scholar
• Bottazzo G.F., Dean B.M., McNally J.M., MacKay E.H., Swift P. G. F., Gamble D.R. In situchar acterization of autoimmune phenomena and expression of HLA molecules in the pancreas in diabetic insulitis. N. Engl. J. Med. 1985; 313: 353–360
   PubMed Web of Science ®Google Scholar
• BenEzra D., Maftzir G., Kalichman I., Barak V. Serum levels of interleukin-2 receptor in ocular Behcet's disease. Am. J. Opthalmol. 1993; 115: 26–30
   PubMed Web of Science ®Google Scholar
• Sedgwick J., Brostoff S., Mason D. Experi mental allergic encephalomyelitis in the absence of a classical delayed-type hypersensitivity reaction. J. Exp. Med. 1987; 165: 1058–1075
   PubMed Web of Science ®Google Scholar
• Airo P., Braga S., Prati E., Brugnoni D., Bettinzioli M., Gorla R., Cattaneo R. Evaluation of serum levels of soluble interleukin-2 receptor as an indicator of disease activity in systemic lupus erythematosus. Clin. Rheumatol. 1992; 11: 97–100
   PubMed Web of Science ®Google Scholar
• Zoumbos N.C., Gascon P., Djeu J.Y., Trost S.R., Young N.S. Circulating activated suppressor T lymphocytes in aplastic anemia. N. Engl. J. Med. 1985; 312: 257–265
   PubMed Web of Science ®Google Scholar